| Literature DB >> 8683484 |
P J Bergman1, E G MacEwen, I D Kurzman, C J Henry, A S Hammer, D W Knapp, A Hale, S A Kruth, M K Klein, J Klausner, A M Norris, D McCaw, R C Straw, S J Withrow.
Abstract
Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights ( < 40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2. Neutropenia was the dose-limiting toxicity in this study.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8683484 DOI： 10.1111/j.1939-1676.1996.tb02031.x
Source DB: PubMed Journal: J Vet Intern Med ISSN： 0891-6640 Impact factor: 3.333